DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Apriso (Mesalamine) - Published Studies

 
 



Apriso Related Published Studies

Well-designed clinical trials related to Apriso (Mesalamine)

Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease. [2011.02]

A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg Twice daily in patients with active mild-to-moderate ulcerative proctitis. [2011.02]

Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. [2010.11]

Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis - a 6-month placebo-controlled trial. [2010.10]

Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. [2010.04]

Survival of the probiotic Escherichia coli Nissle 1917 (EcN) in the gastrointestinal tract given in combination with oral mesalamine to healthy volunteers. [2010.02]

Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. [2010]

Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. [2009.12]

Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. [2009.07]

Comparison of the analgesic effect of ibuprofen with mesalamine after discectomy surgery in patients with lumbar disc herniation: a double-blind randomized controlled trial. [2009.05]

Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis. [2008.12]

Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study. [2008.10]

N-acetyl-L-cysteine combined with mesalamine in the treatment of ulcerative colitis: Randomized, placebo-controlled pilot study. [2008.05.14]

Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. [2007.12]

Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. [2007.01]

Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. [2007.01]

Well-designed clinical trials possibly related to Apriso (Mesalamine)

Abatacept for Crohn's disease and ulcerative colitis. [2012]

Efficacy and safety of Fufangkushen colon-coated capsule in the treatment of ulcerative colitis compared with mesalazine: a double-blinded and randomized study. [2012]

Drug development in inflammatory bowel disease: The role of the FDA. [2011.12]

Individually tailored treatment of medication nonadherence. [2011.10]

Efficacy and safety of Fufangkushen colon-coated capsule in the treatment of ulcerative colitis compared with mesalazine: A double-blinded and randomized study. [2011.09.06]

The efficacy of the combination therapy with oral and topical mesalazine for patients with the first episode of radiation proctitis. [2011.09]

Randomised clinical trial: early assessment after 2 weeks of high-dose mesalazine for moderately active ulcerative colitis - new light on a familiar question. [2011.05]

3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial. [2011.04]

Rectal administration of Lactobacillus casei DG modifies flora composition and Toll-like receptor expression in colonic mucosa of patients with mild ulcerative colitis. [2011.04]

Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis. [2011.03]

Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. [2011.02]

Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine. [2011.01]

Clinical trial: Effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study. [2011.01]

Evaluation of melatonin effectiveness in the adjuvant treatment of ulcerative colitis. [2011]

Curcumin for inflammatory bowel disease: a review of human studies. [2011]

Randomised clinical trial: early assessment after 2 weeks of high-dose mesalazine for moderately active ulcerative colitis - new light on a familiar question. [2011]

Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis. [2011]

Clinical trial: Effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study. [2011]

Aminosalicylates for induction of remission or response in Crohn's disease. [2010.12.08]

E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. [2010.12]

Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. [2010.10]

Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis. [2010.08]

Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis. [2010.08]

Thiopurine maintenance therapy for ulcerative colitis: the clinical significance of monitoring 6-thioguanine nucleotide. [2010.08]

Topical rosiglitazone treatment improves ulcerative colitis by restoring peroxisome proliferator-activated receptor-gamma activity. [2010.07]

Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. [2010.06]

Development of a Web-based concept for patients with ulcerative colitis and 5-aminosalicylic acid treatment. [2010.06]

Oral beclomethasone dipropionate in pediatric active ulcerative colitis: a comparison trial with mesalazine. [2010.04]

Efficacy of 5-ASA in the treatment of colonic diverticular disease. [2010.02]

Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. [2009.11.01]

Chemoprevention of colonic polyps with balsalazide: an exploratory, double-blind, placebo-controlled study. [2009.11]

Safety, efficacy, and pharmacokinetics of balsalazide in pediatric patients with mild-to-moderate active ulcerative colitis: results of a randomized, double-blind study. [2009.11]

In vivo effects of mesalazine or E. coli Nissle 1917 on microsatellite instability in ulcerative colitis. [2009.09.15]

[Maintenance effect of polyglycosides of Tripterygium wilfordii on remission in postoperative Crohn disease] [2009.09]

Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. [2009.08]

Pharmacokinetics and safety of single and multiple doses of Asacol tablets in Japanese healthy volunteers. [2009.08]

The effect of a new symbiotic formulation on plasma levels and peripheral blood mononuclear cell expression of some pro-inflammatory cytokines in patients with ulcerative colitis: a pilot study. [2009.07]

Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. [2009.06]

Recurrence of Crohn's disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial. [2009.05]

Voting With their Feet (VWF) endpoint: a meta-analysis of an alternative endpoint in clinical trials, using 5-ASA induction studies in ulcerative colitis. [2009.03]

Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. [2009.02]

Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. [2009.02]

Budesonide for maintenance of remission in Crohn's disease. [2009.01.21]

Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn's disease: a multicenter, double-blind, randomized, placebo-controlled trial. [2009.01]

Quality of life improvements attributed to combination therapy with oral and topical mesalazine in mild-to-moderately active ulcerative colitis. [2009]

The effect of mesalazine therapy on quality of life in patients with mildly and moderately active ulcerative colitis. [2008.12.01]

Granulocytapheresis versus methylprednisolone in patients with acute ulcerative colitis: 12-month follow up. [2008.11]

Budesonide for induction of remission in Crohn's disease. [2008.07.16]

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. [2008.07]

Can 5-aminosalicylic acid suppository decrease the pain after rectal band ligation? [2008.06.14]

MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations. [2008.06.01]

Mesalazine and/or Lactobacillus casei in maintaining long-term remission of symptomatic uncomplicated diverticular disease of the colon. [2008.05]

Interventions for treating lymphocytic colitis. [2008.04.16]

A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis. [2008.01.07]

Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission. [2008]

Successful Treatment of Steroid Refractory Active Ulcerative Colitis with Natural Interferon-beta - an Open Long-Term Trial. [2007.12]

Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis. [2007.11.01]

Prevention of Complications and Symptomatic Recurrences in Diverticular Disease with Mesalazine: A 12-Month Follow-up. [2007.11]

Thrombin generation in mesalazine refractory ulcerative colitis and the influence of low molecular weight heparin. [2007.10]

Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study. [2007.09]

Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. [2007.09]

Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs. 5-aminosalicylic acid in mild to moderate distal ulcerative colitis. [2007.07.01]

A clinical trial on absorption and N-acetylation of oral and rectal mesalazine. [2007.07]

Systematic review: the potential influence of mesalazine formulation on maintenance of remission in Crohn's disease. [2007.06.15]

Mesalazine with or without cholestyramine in the treatment of microscopic colitis: randomized controlled trial. [2007.06]

Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: A multicenter, randomized, double-blind study. [2007.04]

Is once-daily mesalazine equivalent to the currently used twice-daily regimen? A study performed in 30 healthy volunteers. [2007.03]

Continuous versus cyclic mesalazine therapy for patients affected by recurrent symptomatic uncomplicated diverticular disease of the colon. [2007.03]

Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. [2007.02]

Quality of life in uncomplicated symptomatic diverticular disease: is it another good reason for treatment? [2007]

Spotlight on VSL#3 Probiotic Mixture in Chronic Inflammatory Bowel Diseases. [2007]

Other research related to Apriso (Mesalamine)

Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis. [2012]

Mesalamine in the treatment and maintenance of remission of ulcerative colitis. [2012]

Once-Daily Dosing vs. Conventional Dosing Schedule of Mesalamine and Relapse of Quiescent Ulcerative Colitis: Systematic Review and Meta-Analysis. [2011.12]

Maintaining remission in ulcerative colitis--role of once daily extended-release mesalamine. [2011.02.27]

Small intestinal release mesalamine for the treatment of refractory celiac disease type I. [2011.01]

Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents. [2010.11]

Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. [2010.09]

Inducing and maintaining remission in ulcerative colitis: role of high-dose, extended-release mesalamine. [2010.09]

A Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Mesalamine Suppositories 1 g at Bedtime and 500 mg Twice Daily in Patients with Active Mild-to-Moderate Ulcerative Proctitis. [2010.07.30]

Once-daily mesalamine granules for ulcerative colitis. [2010.07]

Mesalamine protects against colorectal cancer in inflammatory bowel disease. [2010.06]

Impact of a patient-support program on mesalamine adherence in patients with ulcerative colitis--a prospective study. [2010.06]

Mesalamine lung toxicity. [2010.05]

Design of a colonic delivery system based on cationic polymethacrylate (Eudragit E100)-mesalamine complexes. [2010.05]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012